ARIAD Reports Long-term Safety, Efficacy Data of Ponatinib from Phase 2 Pace Trial: 83% of CP-CML Patients Achieved Response

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.